Related Experiment Videos
Interleukin-2: prospects for lymphocyte-mediated destruction of pediatric malignancies
1Department of Pediatrics, University of Wisconsin, Madison.
Abstract:
Immunologic therapy of cancer was speculated on at the turn of the century. In animals, in vitro, and most recently in patients, irrefutable evidence has been obtained that lymphocyte responses can have a reproducible and beneficial antitumor effect. These results indicate that "biologic response modification" may truly become a fourth modality for cancer treatment, to be integrated into the standard approaches of radiation, chemotherapy, and surgery. To what extent these immune approaches may enable eradication of microscopic amounts of residual diseases in children who would otherwise have a recurrence of their malignancies remains the critical issue for testing over the next decade. Enthusiasm regarding this approach is abundant, but critical evaluation of all clinical trials is essential to best focus these mechanisms into effective therapy.
Insights
Immunologic therapy, a potential fourth cancer treatment modality, shows promising antitumor effects in preclinical and clinical studies. Further research is needed to determine its efficacy in eradicating residual disease and preventing recurrence in pediatric cancer patients.
Area of Science:
- Immunology
- Oncology
- Cancer Therapeutics
Background:
- The concept of using the immune system to fight cancer dates back over a century.
- Recent evidence from animal, in vitro, and patient studies confirms that lymphocyte responses can yield beneficial antitumor effects.
Purpose of the Study:
- To evaluate the potential of "biologic response modification" as a novel cancer treatment modality.
- To assess the role of immunologic approaches in eradicating minimal residual disease in pediatric malignancies.
Main Methods:
- Review of preclinical (animal, in vitro) and clinical data on immunologic therapies.
- Analysis of lymphocyte responses and their impact on antitumor effects.
- Evaluation of the potential for immune-based strategies in pediatric oncology.
Main Results:
- Irrefutable evidence supports reproducible and beneficial antitumor effects from lymphocyte responses.
- Biologic response modification is emerging as a potential fourth pillar of cancer treatment alongside surgery, radiation, and chemotherapy.
Conclusions:
- Immunologic therapy holds significant promise for cancer treatment.
- Critical evaluation of ongoing clinical trials is essential to optimize these immune mechanisms for effective cancer therapy, particularly in preventing recurrence in children.